In clinical practice, SGLT2 inhibitors are often initiated first due to their oral administration and broader reimbursement, with GLP-1 receptor agonists subsequently added to address persistent hyperglycemia, excess body weight, or residual albuminuria [84,85]
It can trigger weight (re)gain, a greater appetite, a surge of blood sugar, and lean muscle mass loss with body fat percentage gain
Chromium, often included in weight loss formulations, shows inconsistent effects
One standout in this field is AOD 9604, a peptide gaining popularity for its fat-burning, metabolism-boosting, and joint-supporting properties
The MACS lift has a shorter recovery